IDO1 and sarcoma: In a phase II clinical study, it was found that most sarcoma cells were infiltrated by IDO1-expressing M2 macrophages, resulting in a low response to PD-(L) 1 inhibitor (Munn and Mellor, 2016; Li et al., 2017; Toulmonde et al., 2018).